Company intelligence / Profile preview

ATLyphe

Zürich, Zürich, Switzerlandatlyphe.com ↗

Ownership: Private
Employees: ~5
Development stage: Preclinical

Overview

ATLyphe is developing ALY117, a bispecific T cell engager designed to improve the conditioning step in allogeneic hematopoietic stem cell transplantation. The approach aims to selectively eliminate residual leukemic and stem cells with high precision, reducing toxicity compared to chemotherapy-based regimens. This could increase safety, tolerability, and efficacy for patients with blood diseases such as AML. As of 2025, the company remains preclinical with no reported clinical trial results yet.[3][4][5]

Therapeutic areas: OncologyHematology
Modalities: Bispecific T cell engagersAntibody-based therapies[2][4][6]
Industry: Biotech

Drug pipeline

1 asset

ALY117

Preclinical

Partnerships

Supported by Wyss Zurich Innovation Hub[4]

Beyond the preview

Go deeper on ATLyphe.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATLyphe.

Explore the full profile